XFOR News and Press, X4 Pharmaceuticals Inc. From 03/21/24

2024-03-21 11:35:28 ET X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Conference Call March 21, 2024, 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Mark Bald...

2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

2024-03-21 06:08:16 ET More on X4 Pharmaceuticals Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pharmaceuticals Financial information for X4 Pharmaceuticals Read the full article on Seeking Alpha For further...

Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and initiation of global Phase 3 clinical trial of mavorixafor for the treatment of certain chro...

2024-03-20 11:48:44 ET More on X4 Pharmaceuticals Seeking Alpha’s Quant Rating on X4 Pharmaceuticals Historical earnings data for X4 Pharmaceuticals Financial information for X4 Pharmaceuticals Read the full article on Seeking Alpha For further...

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, ...

2023-12-13 23:43:55 ET Summary X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutro...

2023-12-12 15:25:46 ET More on X4 Pharmaceuticals X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript X4 Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares X4 shares ju...

Initial data continue to support advancement of mavorixafor into pivotal, global Phase 3 trial in certain chronic neutropenic disorders; company on track to initiate in 1H 2024 X4 expects to present additional CN Phase 2 clinical trial data in 1H 2024 BOSTON, Dec. 09, 2023 (GLOBE ...